Markus Warmuth

18.8k total citations
48 papers, 3.1k citations indexed

About

Markus Warmuth is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Markus Warmuth has authored 48 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 23 papers in Molecular Biology and 16 papers in Genetics. Recurrent topics in Markus Warmuth's work include Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Cancer-related Molecular Pathways (6 papers). Markus Warmuth is often cited by papers focused on Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Cancer-related Molecular Pathways (6 papers). Markus Warmuth collaborates with scholars based in United States, Germany and Switzerland. Markus Warmuth's co-authors include Michael Hallek, Christine Dierks, Katja Zirlik, Hendrik Veelken, Doriano Fabbro, S. Danhauser-Riedl, Gang Xia, Paul W. Manley, Marion Dorsch and Nathanael S. Gray and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Markus Warmuth

45 papers receiving 3.1k citations

Peers

Countries citing papers authored by Markus Warmuth

Since Specialization

Citations

This map shows the geographic impact of Markus Warmuth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Warmuth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Warmuth more than expected).

Fields of papers citing papers by Markus Warmuth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Warmuth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Warmuth. The network helps show where Markus Warmuth may publish in the future.

Co-authorship network of co-authors of Markus Warmuth

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Warmuth. A scholar is included among the top collaborators of Markus Warmuth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Warmuth. Markus Warmuth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity 2019 ·Journal of Biological Chemistry ·Tuong-Vi Nguyen, Shihua Yao, Yahong Wang, Alan Rolfe, Anand Selvaraj, Rachel Darman, Jiyuan Ke, Markus Warmuth, Peter G. Smith, Nicholas Larsen, (unknown), Ping Zhu, Peter Fekkes, Frédéric H. Vaillancourt, David M. Bolduc	22
2	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA) 2018 ·Cancer Chemotherapy and Pharmacology ·Nathalie Rioux, Sherri Smith, Manav Korpal, (unknown), Sudeep Prajapati, Guo Zhu Zheng, Markus Warmuth, Peter G. Smith	14
3	Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion 2017 ·PLoS ONE ·Lee A. Albacker, Jeremy Wu, Peter Smith, Markus Warmuth, Philip J. Stephens, Ping Zhu, Lihua Yu, Juliann Chmielecki	83
4	Implementation of <em>In Vitro</em> Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms 2015 ·Journal of Visualized Experiments ·Manav Korpal, Jacob Feala, Xiaoling Puyang, Jian Zou, Alex H. Ramos, Jeremy Wu, (unknown), Lihua Yu, Markus Warmuth, Ping Zhu	2
5	Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas 2011 ·Cancer Research ·Tara L. Naylor, Huaping Tang, Boris A. Ratsch, Andreas Enns, Alice Loo, Liqing Chen, Peter Lenz, Nigel J. Waters, W. Schüler, Bernd Dörken, Yung‐Mae Yao, Markus Warmuth, Georg Lenz, Frank Stegmeier	88
6	The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells 2010 ·Cancer Research ·Zainab Jagani, Dmitri Wiederschain, Alice Loo, Dan He, Rebecca Mosher, Paul Fordjour, John E. Monahan, Michael Morrissey, (unknown), Christoph Lengauer, Markus Warmuth, William R. Sellers, Marion Dorsch	48
7	The ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease 2010 ·Cancer Research ·Christine Dierks, Francisco Adrián, Paul Fisch, Hong Ma, (unknown), (unknown), (unknown), (unknown), Guoxun Liu, Sabine Rottmann, (unknown), Katja Zirlik, Hendrik Veelken, Markus Warmuth	51
8	Allosteric inhibition of BCR-ABL 2010 ·Cell Cycle ·Amr Hassan, Sreenath V. Sharma, Markus Warmuth	23
9	Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation 2008 ·Cancer Cell ·Christine Dierks, (unknown), (unknown), Katja Zirlik, Mario Stegert, Paul W. Manley, (unknown), Annette Schmitt‐Graeff, (unknown), Hendrik Veelken, Markus Warmuth	407
10	Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase 2008 ·Bioorganic & Medicinal Chemistry Letters ·Wooyoung Hur, Anastasia Velentza, Sung Joon Kim, (unknown), Xinnong Jiang, (unknown), Daniel E. Mason, (unknown), (unknown), Jianming Zhang, Anna Zagórska, Michael DiDonato, A. S. Nagle, Markus Warmuth, Steven P. Balk, Eric C. Peters, Nathanael S. Gray	32
11	Role of p21WAF1/CIP1 as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells 2007 ·Annals of Hematology ·(unknown), Axel Obermeier, (unknown), (unknown), Markus Warmuth, Günter Krause, Michael Hallek	15
12	Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK 2006 ·Proceedings of the National Academy of Sciences ·Anna Galkin, (unknown), Sung Joon Kim, Tami Hood, Nanxin Li, Lintong Li, Gang Xia, Ruo W. Steensma, (unknown), Jiqing Jiang, Yongqin Wan, (unknown), Yi Liu, Fangxian Sun, Peter G. Schultz, Nathanael S. Gray, Markus Warmuth	289
13	Profiling the kinome for drug discovery 2006 ·Drug Discovery Today Technologies ·S. Frank Yan, Frederick J. King, Yingyao Zhou, Markus Warmuth, Gang Xia	3
14	Ba/F3 cells and their use in kinase drug discovery 2006 ·Current Opinion in Oncology ·Markus Warmuth, Sung Joon Kim, Xiang-ju Gu, Gang Xia, Francisco Adrián	153
15	A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors 2006 ·Chemistry & Biology ·Okram Barun, A. S. Nagle, Francisco Adrián, Christian Lee, Pingda Ren, Xia Wang, Taebo Sim, Yongping Xie, Xing Wang, Gang Xia, Glen Spraggon, Markus Warmuth, Yi Liu, Nathanael S. Gray	124
16	The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains 2003 ·Leukemia ·Michael Stanglmaier, Markus Warmuth, (unknown), (unknown), Michael Hallek	55
17	Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia 2003 ·Current Pharmaceutical Design ·Markus Warmuth, Robert Damoiseaux, Yi Liu, Doriano Fabbro, Nathanael S. Gray	92
18	Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies 1999 ·Annals of Hematology ·Markus Warmuth, S. Danhauser-Riedl, Michael Hallek	60
19	The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr 1997 ·Journal of Biological Chemistry ·Markus Warmuth, Michael Bergmann, (unknown), (unknown), Bertold Emmerich, Michael Hallek	104
20	Interaction of the receptor tyrosine kinase p145^c‐kit with the p210^bcr/abl kinase in myeloid cells 1996 ·British Journal of Haematology ·Michael Hallek, S. Danhauser-Riedl, Ronald Herbst, Markus Warmuth, (unknown), (unknown), Brian Druker, J D Griffin, Bertold Emmerich, A. Ullrich	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact